Patents by Inventor Hilary Shmeeda
Hilary Shmeeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220087975Abstract: A liposome composition comprising a lipophilic prodrug of mitomycin C having an improved pharmacokinetic profile is described. A method for preparing the composition with a solvent system comprised of ethanol and tertiary butanol mixed at an adequate ratio is also described. In an embodiment, the liposome composition is a population of lipid nanoparticles and a pharmaceutically acceptable vehicle, wherein the population of lipid nanoparticles is comprised of a first fraction of spherical liposomes and a second fraction of rod-shaped lipid nanoparticles, where the second fraction is less than about 15% of the population of lipid nanoparticles.Type: ApplicationFiled: January 11, 2020Publication date: March 24, 2022Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
-
Patent number: 10617672Abstract: A composition comprising liposomes comprising a lipid layer defining an internal aqueous compartment, an anthracycline drug entrapped in the internal aqueous phase and mitomycin C prodrug incorporated into the lipid layer is described.Type: GrantFiled: October 14, 2016Date of Patent: April 14, 2020Assignees: Lipomedix Pharmaceuticals Ltd., Shaare Zedek Scientific Ltd.Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
-
Publication number: 20180296529Abstract: A composition comprising liposomes comprising a lipid layer defining an internal aqueous compartment, an anthracycline drug entrapped in the internal aqueous phase and mitomycin C prodrug incorporated into the lipid layer is described.Type: ApplicationFiled: October 14, 2016Publication date: October 18, 2018Inventors: Alberto GABIZON, Patricia OHANA, Hilary SHMEEDA
-
Patent number: 10085940Abstract: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as ?? T-cells.Type: GrantFiled: July 12, 2012Date of Patent: October 2, 2018Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., KINGS COLLEGE LONDON, SHAARE ZEDEK SCIENTIFIC LTD.Inventors: Alberto A. Gabizon, Yechezkel Barenholz, Hilary Shmeeda, John Maher, Ana Catarina Parente Pereira
-
Patent number: 10080807Abstract: The present invention is based on a finding of an unexpected synergistic and safe combination of antineoplastic agents which when administered in combination provides greater efficacy than the single agents alone. Accordingly, a method of treating neoplasia in a subject in need of treatment is provided, by administering to the subject an amount of a prodrug of mitomycin C that yields a therapeutically effective amount of mitomycin C, in combination with an amount of a chemotherapeutic agent. In one embodiment, the prodrug of mitomycin C is a liposomal-prodrug of mitomycin C. Together, the prodrug of mitomycin C and chemotherapeutic agent provide a synergistic antineoplastic effect.Type: GrantFiled: June 9, 2015Date of Patent: September 25, 2018Assignees: Lipomedix Pharmaceuticals Ltd., Shaare Zedek Scientific Ltd.Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
-
Publication number: 20170112807Abstract: The present invention is based on a finding of an unexpected synergistic and safe combination of antineoplastic agents which when administered in combination provides greater efficacy than the single agents alone. Accordingly, a method of treating neoplasia in a subject in need of treatment is provided, by administering to the subject an amount of a prodrug of mitomycin C that yields a therapeutically effective amount of mitomycin C, in combination with an amount of a chemotherapeutic agent. In one embodiment, the prodrug of mitomycin C is a liposomal-prodrug of mitomycin C. Together, the prodrug of mitomycin C and chemotherapeutic agent provide a synergistic antineoplastic effect.Type: ApplicationFiled: June 9, 2015Publication date: April 27, 2017Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
-
Publication number: 20140328899Abstract: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as ?? T-cells.Type: ApplicationFiled: July 7, 2012Publication date: November 6, 2014Applicants: SHAARE ZEDEK MEDICAL CENTER, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Alberto A. Gabizon, Yechezkel Barenholz, Hilary Shmeeda
-
Publication number: 20120100206Abstract: The present is based on the finding that folate targeted liposomal alendronate (FT-AL-L) was significantly more potent against two tested cancer cell lines than the free alendronate (AL) or the non-targeted liposomal alendronate (AL-L), as observed by the increased cytotoxicity of the folate targeted liposomal alendronate. Thus, the present disclosure provides targeted liposomes comprising a membrane and an intraliposomal core, the membrane comprising at least one liposome forming lipid and a targeting moiety, such as folate, exposed at the membrane's outer surface; and the intraliposomal core comprising encapsulated therein least one N-containing bisphosphonate. Also provided by the present disclosure are methods of use of the targeted liposomes such as for the treatment of a disease or disorder.Type: ApplicationFiled: June 10, 2010Publication date: April 26, 2012Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.Inventors: Hilary Shmeeda, Alberto A. Gabizon
-
Patent number: 6235308Abstract: A method of treating hypertension and related symptoms thereof is described. A suspension of small, unilamellar vesicles composed primarily of phospholipids similar in nature to those of egg phosphatidylcholine is administered parenterally to a subject in need of such treatment repeatedly and over an extended period of time of at least several days, until a significant drop in blood pressure is observed.Type: GrantFiled: June 10, 1994Date of Patent: May 22, 2001Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Hilary Shmeeda
-
Patent number: 5948756Abstract: A lipoprotein particle and a therapeutic lipoprotein composition are disclosed. The lipoprotein particle consists essentially of lecithin phospholipids with low phase transition temperatures and human apoproteins A and C. A therapeutic composition for therapeutic administration to a subject, comprising the lipoprotein particles of the invention, is also disclosed. The composition is useful is treating disease conditions associated with elevated serum Lp(a) levels, as well as hypertension and acute renal failure.Type: GrantFiled: August 31, 1995Date of Patent: September 7, 1999Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Hilary Shmeeda, Tova Chajek
-
Patent number: 5914311Abstract: A method of reducing serum Lp(a) concentration in a subject is accomplished by administration of liposomes. A suspension of small, unilamellar vesicles composed primarily of phosphatidylcholine phospholipids is administered parenterally to a subject having or at risk for developing a disease condition associated with an elevated serum Lp(a) concentration. The liposomes are infused over a period of time such that a significant drop in serum Lp(a) concentration is observed.Type: GrantFiled: May 19, 1998Date of Patent: June 22, 1999Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Hilary Shmeeda, Tova Chajek
-
Patent number: 5741514Abstract: A method of reducing the serum Lp(a) concentration in a subject is disclosed. A suspension of small, unilamellar vesicles composed primarily of phospholipids, similar in nature to those of egg phosphatidylcholine, is administered parenterally to a subject having or at risk for developing a disease condition associated with an elevated serum Lp(a) concentration. In the method, liposomes are infused over an extended period of time of at least several weeks, until a significant drop in serum Lp(a) concentration is observed.Type: GrantFiled: August 31, 1995Date of Patent: April 21, 1998Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Hilary Shmeeda, Tova Chajek